Artificial intelligence and machine learning-assisted digital applications for biopharmaceutical manufacturing.

Area of Science:

• Biopharmaceutical Manufacturing
• Artificial Intelligence in Medicine
• Process Automation

Background:

• Biologics manufacturing (monoclonal antibodies, cell, and gene therapies) is more complex than traditional small molecule drug production.
• Artificial intelligence (AI) and automation are increasingly vital for addressing these complexities.
• Existing AI/ML applications demonstrate potential in enhancing biomanufacturing operations.

Purpose of the Study:

• To highlight the essential role of AI and automation in biopharmaceutical manufacturing.
• To discuss the benefits of AI applications in producing biologics more efficiently and economically.
• To underscore the impact of AI on process understanding, monitoring, and regulatory compliance.

Main Methods:

• Review of current AI and machine learning (ML) applications in the biopharmaceutical industry.
• Analysis of advancements in AI/ML research and cloud technologies.
• Examination of existing AI/ML use cases in monoclonal antibody manufacturing.
• Consideration of future benefits for cell and gene therapies.

Main Results:

• AI applications are being implemented to boost operational efficiency, process understanding, and monitoring.
• AI adoption is accelerated by regulatory guidance and advancements in AI/ML and cloud technologies.
• Successful AI/ML applications are already present in monoclonal antibody production.
• Cell and gene therapies are poised to significantly benefit from AI integration.

Conclusions:

• AI and automation are essential for the rapid and cost-effective manufacturing of complex biologics.
• AI integration improves critical aspects of biomanufacturing, including regulatory compliance.
• Advancements in AI/ML and cloud platforms facilitate the development and deployment of these transformative technologies.
• The strategic implementation of AI will ultimately lead to better patient care through improved biologic therapies.